Glyco

GlycoEra is a biotechnology company pioneering a new class of biologics called extracellular protein degraders to transform the treatment of autoimmune diseases. By leveraging its proprietary CustomGlycan platform, the company engineers bispecific molecules that selectively target and degrade circulating, disease-causing proteins through naturally occurring clearance pathways. Its lead program, GE8820, is designed to achieve deep and rapid degradation of pathogenic IgG4 autoantibodies, offering a precision immunology approach that avoids the broad immunosuppression associated with traditional therapies. Headquartered in Switzerland and Massachusetts, GlycoEra is advancing a robust pipeline of precision medicines aimed at improving outcomes for patients with high unmet medical needs.